CIM
EBS icon

Calvert Investment Management’s Emergent Biosolutions EBS Stock Holding History

Calvert Investment Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-97,908
Closed -$3.21M – 186
2016
Q4 		$3.21M Sell
97,908
-13,930
-12% -$418K 0.12% 234
2016
Q3 		$3.53M Buy
+111,838
New +$3.25M 0.13% 221

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
AAM
Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Calvert Investment Management's EBS Position: Q1 2017 in Review

Calvert Investment Management sold out of Emergent Biosolutions (EBS) in Q1 2017, closing a stake of 97,908 shares — an estimated $3.21M sold.

Calvert Investment Management first reported a position in EBS in Q3 2016 and held it in 2 quarters. The position peaked at $3.53M in Q3 2016. 176 funds tracked by Wall St. Rank hold EBS as of Q1 2017.

  • Calvert Investment Management reported no remaining Emergent Biosolutions position as of Q1 2017 after selling out during the quarter.
  • Calvert Investment Management sold 97,908 Emergent Biosolutions shares in Q1 2017, an estimated $3.21M.
  • Calvert Investment Management first reported a position in Emergent Biosolutions in Q3 2016 and held it in 2 quarters.
  • Calvert Investment Management's Emergent Biosolutions position peaked at $3.53M in Q3 2016.
  • 176 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2017.

Based on Calvert Investment Management's 13F filing for Q1 2017.